Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company isable to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases.

Biotechnology

Health Care

Pharmaceutical

Therapeutics

Draupnir Bio

The Copenhagen office serves as a strategic oversight hub, facilitating governance and collaboration within the organization.

Copenhagen

Draupnir Bio's headquarters in Risskov, Denmark

Andrew Hotchkiss

Simon Glerup

Casper Tind Hansen

This department focuses on the study and application of biological principles and processes, particularly in vitro methods and research.

Biology Department

This department oversees organizational governance and board-related activities.

Board Governance

This department defines the strategic direction and overall management of the organization.

Executive Leadership

This department manages laboratory operations and supports research activities through effective resource and personnel management.

Laboratory Services

This department focuses on advancing scientific knowledge and developing innovative solutions in the field of biotechnology.

Draupnir Bio

Org chart

Teams

Biology Department

Board Governance

Executive Leadership

Laboratory Services

Research and Development

Offices

Draupnir Bio

Org chart

Teams

Biology Department

Board Governance

Executive Leadership

Laboratory Services

Research and Development

Offices

Related companies